⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL212125 | 1.00 | — | — | |
| SCHEMBL212161 | 0.98 | TSHR (0.42) | — | |
| SCHEMBL212160 | 0.98 | TSHR (0.42) | — | |
| SCHEMBL212743 | 0.98 | TSHR (0.42) | — | |
| SCHEMBL212744 | 0.98 | TSHR (0.42) | — | |
| SCHEMBL28448373 | 0.98 | TSHR (0.42) | — | |
| SCHEMBL15611604 | 0.98 | TSHR (0.42) | — | |
| SCHEMBL15611606 | 0.98 | TSHR (0.42) | — | |
| SCHEMBL27441419 | 0.98 | TSHR (0.42) | — | |
| SCHEMBL12757015 | 0.98 | TSHR (0.42) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103889969-A | Novel process | GIVAUDAN SA | 2014-06-25 | — | — | CN | claimed |
| US-20120077941-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | US | claimed |
| US-8088868-B2 | oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis | BRIDGESTONE CORPORATION (JP) | 2012-01-03 | — | — | US | claimed |
| US-20080146745-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2008-06-19 | — | — | US | claimed |
| US-9603895-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| CN-103889969-A | Novel process | GIVAUDAN SA | 2014-06-25 | — | — | CN | disclosed |
| US-8541509-B2 | Polymers functionalized with protected oxime compounds | BRIDGESTONE CORPORATION (JP) | 2013-09-24 | — | — | US | disclosed |
| US-8367618-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120077941-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2012-03-29 | — | — | US | disclosed |
| US-8088868-B2 | oximation of cojugated homopolymers formed by addtion polymerization of conjugated diene monomer in the presence lanthanide copmpounds as polymerization catalysts; polymers used in the manufacture of tires having reduced hysteresis | BRIDGESTONE CORPORATION (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20080146745-A1 | POLYMERS FUNCTIONALIZED WITH PROTECTED OXIME COMPOUNDS | BRIDGESTONE CORPORATION (JP) | 2008-06-19 | — | — | US | disclosed |